Physiologically based pharmacokinetic (PBPK) modeling involves mathematically describing the complex interplay of the critical physicochemical and biological determinants involved in the disposition of chemicals. In this approach, the body is divided into a number ofbiologically relevant tissue compartments, arranged in an anatomically accurate manner, anddefined with appropriae physiologicalcharacteristic The extapolation ofpharmaconeicbehavior ofeas from high dose to low dose for various exposure routes and species is possible with this approach because these models are developed by integrating quantitative information on the critical determinnts ofcemi disposition undera biological modeling framework. The principal application of PBPK models is in the prediction of tissue dosimetry of toxic moiety (e.g., parent chemical, reactive metabolite, macromolecular adduct) of a chemical. Such an application has been demonstrated with dichloromethane, a liver and lung carcinogen in the B6C3F~mouse. The PBPK model-based risk assessment approach estimated a cancer risk to people of3.7x10-8 for a lifetime inhalation exposure of 1 Ag/m3, which is lower by more than two orders of magnitude than that calculated by the U.S. Environmental Protection Agency using the linearized multistage model (for low-dose extrapolation) and body surface correction factor (for interspecies scaling).
Introduction
The process of risk assessment for chemical carcinogens is conducted in four parts: hazard identification, dose-response assessment, exposure assessment, and risk characterization (1) . Dose-response assessment entails both high-dose to low-dose and interspecies extrapolation ofthe tissue response. These extrapolations are usually conducted with "mandated" models, a linearized multistage (LMS) cancer model for the low dose, and a body surface or body weight correction for interspecies extrapolation (2) . In the LMS model, the independent variable, dose, is most usually regarded simply as administered dose or inhaled concentration during the bioassay exposure period. Lowdose extrapolation activities consist of the extrapolation ofboth tissue dosimetry and response. Nonlinearities in either or both of these processes can influence the tumor outcome depending on whether the mechanism oftumor induction is dose-invariant. The assessment of risk associated with exposure to chemicals should be based on all the biologically relevant mechanistic data, and not simply on the administered dose, thus enabling a more accurate estimation of actual risk. This paper discusses the methodological aspects of extrapolating tissue dosimetry with the use ofphysiological pharmacokinetic models and presents an example of use of such a model to improve the assessment of tumorigenic risk associated with human exposure to dichloromethane.
Physiologically Based Pharmacokinetic Modeling
Physiologically based pharmacokinetic (PBPK) modeling involves the computer simulation ofthe uptake and disposition of chemicals based on (5) . The toxic moiety responsible for DCM tumorigenicity has not been identified; however, it is known that potentially reactive intermediates are produced by two major metabolic pathways (6) (7) (8) . DCM is metabolized in both target organs by a cytochrome P-450-mediated oxidative pathway that yields formyl chloride and by conjugation with glutathione (GSH) yielding chloromethyl glutathione. Using the PBPK modeling approach, information on tissue dosimetry of parent chemical and its metabolites in the most sensitive test species (i.e., mouse) was obtained (4) . Target-tissue exposure to an appropriate dose surrogate was related to the tumor levels seen in the National Toxicology Program (NTP) bioassay to derive the acceptable target dose and external exposure concentration for humans. These predictions were then compared to those obtained with the conventional risk assessment approach adopted by the U.S. Environmental Protection Agency (U.S. EPA).
Model Development
The PBPK model for DCM consisted of the following tissue compartments: liver, lung, fat, slowly perfused tissues, and richly perfused tissues. The rate ofchange in the amount ofDCM in the tissue compartments (dA,/dt) was described by a series of mass-balance differential equations of the following form: The physiological parameters required for the PBPK model (i.e., alveolar ventilation rate, blood flow rates, tissue volumes) were obtained from the literature (9,10). The blood:air and tissue:air partition coefficients for DCM were determined by vial equilibration techniques (11, 12) . The tissue:blood partition coefficients required for the model were determined by dividing tissue:air values by the blood:air value. The rate constants for DCM metabolism were determined by apportioning the wholebody metabolic capacity between lung and liver by assuming that the distribution ofenzyme activities metabolizing DCM was the same as the distribution ofenzyme activities acting on two model substrates, 7-ethoxycoumarin for microsomal oxidation, and 2,5-dinitrochlorobenzene for GSH conjugation (13 ficients for humans were calculated by dividing mouse tissue:air partition coefficients by human blood:air partition coefficient. Further, the metabolic rate constants for humans were estimated from volunteer human exposure studies, in which levels of DCM and carboxyhemoglobin in blood were determined during and following a 6-hr exposure to 100 and 350 ppm DCM (14) . The glutathione S-transferase activity (GST) in humans was set equal to the highest activity reported in rodents.
Choice of Dose Surrogate
The mouse PBPK model for DCM, formulated by integrating information on mouse physiology, DCM solubility characteristics, and metabolic rate constants, was successfully used to describe the disposition of DCM (4) . The mouse PBPK model was then used to calculate the tissue dose of metabolites and parent chemical arising from exposure scenarios comparable to those of the NTP bioassay studies. Their relationship to the observed tumor incidence was examined. Because DCM is very unreactive, it is unlikely to be directly involved in its tumorigenicity. Hence the relationship between the tissue exposure to its metabolites and tumor incidence was examined (Table 1) . Whereas the dose surrogate based on the oxidative pathway did not vary between DCM exposure concentrations of 2000 and 4000 ppm, the flux through the GSH conjugation pathway did correspond well with the degree ofDCM-induced cancer at these 
High-Dose to Low-Dose Extrapolation
The model prediction of the target tissue dose of the DCM-GSH conjugate resulting from 6-hr inhalation exposures of 1-4000 ppm of DCM is presented in Figure 3 . The estimation of target tissue dose of DCM-GSH conjugate by linear backextrapolation gives rise to a 21-fold higher estimate than that obtained by the PBPK modeling approach. This discrepancy arises from the nonlinear behavior of DCM metabolism at high exposure concentrations. At exposure concentrations exceeding 300 ppm, the cytochrome P-450-mediated oxidation pathway is saturated, giving rise to a corresponding disproportionate increase in the flux through the GSH conjugation pathway.
Interspecies Extrapolation
The interspecies extrapolation of DCM disposition behavior was possible because the critical biological determinants of disposition were first identified in the test species, the mouse. Thus, the physiological parameters were scaled allometrically, the metabolic parameters were determined experimentally and the tissue:air partitioning of DCM was assumed to be speciesinvariant. The PBPK model adequately simulated the blood levels of DCM observed in humans after a 6-hr inhalation exposure to 100 or 350 ppm DCM (Fig. 4) . The target tissue dose for humans was estimated to be some 2.7 times lower than that for the mouse. Considering these data, the human tissue dose of DCM-GSH conjugate for a 6-hr exposure to 1 ppm DCM is expected to be some 57 times lower than that expected by linear extrapolation of its behavior at high doses, such as the doses used in the mouse bioassay (4).
Risk Assessment
The cancer risk assessment for DCM was conducted using the LMS model to relate tissue dose of DCM-GSH metabolite (rather than DCM exposure concentration) to the observed tumor incidence rates at high exposure concentrations in the mouse. In assessing the tumorigenic risks associated with human exposure to this chemical, it was assumed that humans are as sensitive as the most sensitive target species. Therefore, equal target tissue doses are expected to produce similar tumor incidence regardless ofthe species. This conclusion is in contrast to that obtained by the EPA, which estimates that people are more sensitive than mice, based on the use of a surface-area scaling approach (17) . In the human DCM risk assessment based on the PBPK model using the GST pathway dose, the predicted human lowlose cancer risk was about 100-to 200-fold less than that estimated by the EPA using their standard default assumptions (4) . 
Issues Surrounding the Use of PBPK Models in Risk Assessment
The motivation for use ofPBPK models in toxicology research is to uncover the biological determinants of tissue dosimetry. These models are part ofa systematic approach to studying how chemicals gain entry to, distribute within, and are eliminated from the body. These models are complex with multiple parameters, but in this regard they simply reflect some ofthe obvious complexities of the biological system.
One strategy for accurately estimating specific parameters is to conduct kinetic studies under conditions where pharmacokinetic behavior ofchemicals is related to one or two dominant factors and thereby derive estimates of the value of these parameters. An example is the estimation of metabolic parameters by gas uptake studies (20) . Alternatively, biochemical and chemical-specific parameters may be directly estimated in some cases from studies with in vitro preparations (18) or obtained from the literature (21) .
Parameter identifiability and model overspecification are problems inherent in these PBPK models or in any other multiparameter model. Direct measurement ofmodel parameters by experimental methods, independent of analysis of tissue timecourse curves, is the preferred approach. Nonetheless, limited numbers of parameters will often still have to be estimated by analysis of time-course data by curve-fitting techniques, under well-defined experimental conditions where the curves are particularly sensitive to the parameter of interest.
Other Despite these unresolved issues, PBPK models are becoming more widespread in many areas oftoxicology research (23, 24) . We are beginning to see more examples of application of these models for the assessment of tumorigenic risk associated with human exposure to chemicals (25) (26) (27) . The PBPK modeling addresses only the tissue dose aspect of the exposure-dose-response continuum. Detailed knowledge ofall aspects ofthe continuum is required to improve risk assessment. The PBPK model-based risk assessments have used these models to estimate tissue dose but still rely on LMS approach as the response model. Biologically based response models are also being developed for use in risk assessment (28, 29) . Fully linked dosimetry-response simulation models promise to integrate a diversity of pharmacokinetic, mechanistic, and tumor progression studies into a unitary description ofchemical carcinogenesis (30, 31) . These integrated biological models should greatly improve the scientific basis of low-dose and interspecies extrapolation of tissue dosimetry and response.
